AUTHORS
Bouthaina S. Dabaja, MD, Paolo Strati, MD2, Jillian R. Gunther, MD PhD3, Lei Feng, MS4, Gamar Alizani5, Susan Y. Wu, MD6, Dai Chihara, MD, PhD7, Sara El Mustapha, MD8, Jason Westin, MD, MS, FACP, FASCO9, Sairah Ahmed, MD10, Ranjit Nair, MD11, Penny Q. Fang12, Timothy A. Lin, MD13, Omran Saifi, MD14, Chijioke C Nze, MD, MPH15, Luis Malpica, MD16, Luis E. Fayad, MD17, Nathan Comeaux18, Shryll Turner, APRN19, Francisco Vega Sr, MD PHD20, Swaminathan P. Iyer, MD21, Sattva S Neelapu Sr, MD22, Chelsea C. Pinnix, MD, PhD23
AFFILIATIONS
1 UT MD Anderson Cancer Center, Houston, Texas, United States
2 UT MD Anderson Cancer Center, Houston, Texas, United States
3 UT MD Anderson Cancer Center, Houston, Texas, United States
4 UT MD Anderson Cancer Center, Houston, Texas, United States
5 UT MD Anderson Cancer Center, Houston, Texas, United States
6 UT MD Anderson Cancer Center, Houston, Texas, United States
7 UT MD Anderson Cancer Center, Houston, Texas, United States
8 UT MD Anderson Cancer Center, Houston, Texas, United States
9 UT MD Anderson Cancer Center, Houston, Texas, United States
10 UT MD Anderson Cancer Center, Houston, Texas, United States
11 UT MD Anderson Cancer Center, Houston, Texas, United States
12 UT MD Anderson Cancer Center, Houston, Texas, United States
13 UT MD Anderson Cancer Center, Houston, Texas, United States
14 UT MD Anderson Cancer Center, Houston, Texas, United States
15 UT MD Anderson Cancer Center, Houston, Texas, United States
16 UT MD Anderson Cancer Center, Houston, Texas, United States
17 UT MD Anderson Cancer Center, Houston, Texas, United States
18 UT MD Anderson Cancer Center, Houston, Texas, United States
19 UT MD Anderson Cancer Center, Houston, Texas, United States
20 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 UT MD Anderson Cancer Center, Houston, Texas, United States
22 UT MD Anderson Cancer Center, Houston, Texas, United States
23 UT MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: Involved Site Radiation Therapy (ISRT) is the standard treatment for patients with early-stage follicular lymphoma (FL), achieving local complete remission and control exceeding 90%, and potentially offering cure. However, relapse outside the initial and irradiated location is common, with less than 50% of patients remaining relapse-free and potentially cured after 10 years from diagnosis. Optimizing treatment to control systemic relapse while limiting treatment-related toxicity has been challenging due to the lack of randomized trials. To investigate the hypothesis that adding systemic therapy such as Rituximab to ISRT could improve progression-free survival, we conducted a randomized controlled trial in which patients were assigned to ISRT alone or to ISRT concurrently with Rituximab, followed by Rituximab maintenance.
Methods: The Randomized controlled trial was approved and conducted according to institutional review board guidelines. We enrolled patients with stage I-II (confirmed by PET-CT and negative bone marrow biopsy), pathologically confirmed FL (grade 1, 2, or 3a). Patients were randomly assigned to either arm A: ISRT 24 Gy in 12 fractions, or arm B: ISRT 24 Gy concurrently with Rituximab (ISRT+R) weekly (375mg/m2) for 4 weeks, followed by 4 consecutive doses given every 2 months over an 8-month period. The primary endpoint was progression-free survival (PFS). Given that the last patients enrolled are still being followed, and per approval from the institutional regulatory body, a descriptive analysis was performed, and the Kaplan-Meier method was used to estimate PFS and overall survival (OS).
Results: Between 2013 and 2025, 79 patients were enrolled and randomized, 39 in arm A and 40 in arm B. At randomization, median age was 58 years; 37 (47%) were female; 54 (73%) were stage I; 62 (82%) were grade 1or 2; median size of presenting tumor was 2.4 cm; median max SUV was 7. With a median follow-up of 57 months (range 40-65 months), Local complete remission and control were 95%; one local recurrence, at the original presenting site, was observed in arm A (ISRT) and 3 in arm B (ISRT+R). Recurrence outside of the original presenting site was observed in 10 patients in arm A (ISRT) and 3 in arm B (ISRT+R), one of whom had both local and systemic recurrence. The improved 3-and 5-year PFS rates were observed in arm B (ISRT+R) (97% for both; 95% CI 92-100%) compared to arm A (ISRT) (87%: 95% CI 76-100 % and 64%: 95 CI 47-87%). The median OS has not been reached. Two patients transformed to large cell lymphoma (both in arm B). No treatment-related grade 3 or 4 toxicity was observed; there was one death in each of the two arms; both patients died from unrelated causes.
Conclusion: Improved PFS was observed with the addition of Rituximab to radiation compared with ISRT alone; this could change the standard of care and offer a more effective treatment approach.
DISCLOSURES
Bouthaina S. Dabaja, MD: No relevant conflicts of interest to declare.